Jain Global LLC Makes New Investment in McKesson Corporation $MCK

Key Points

• Jain Global LLC initiated a new position in McKesson, buying 15,299 shares in Q3 valued at about $11.82 million, while institutional investors now own roughly 85.07% of the stock.
• McKesson beat the quarter with EPS of $9.34 and revenue of $106.16B, issued FY2026 guidance of 38.80–39.20 EPS, and analysts hold a consensus price target near $960.93 with several firms raising targets above $1,000.
• Company insiders have been net sellers recently — EVP Michele Lau sold 2,725 shares at about $990 and insiders disposed of 3,868 shares (~$3.74M) over the last 90 days, leaving insider ownership near 0.08%.

Jain Global LLC acquired a new position in shares of McKesson Corporation (NYSE:MCK - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 15,299 shares of the company's stock, valued at approximately $11,819,000.

Other hedge funds also recently modified their holdings of the company. J.W. Cole Advisors Inc. boosted its position in shares of McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company's stock worth $3,931,000 after purchasing an additional 1,329 shares in the last quarter. Private Wealth Partners LLC increased its position in McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company's stock valued at $24,598,000 after buying an additional 1,682 shares in the last quarter. AlphaQuest LLC raised its stake in McKesson by 91.2% during the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company's stock worth $1,365,000 after buying an additional 843 shares during the period. CW Advisors LLC raised its stake in McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company's stock worth $8,067,000 after buying an additional 8,130 shares during the period. Finally, Envestnet Asset Management Inc. boosted its holdings in McKesson by 12.4% in the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company's stock worth $255,438,000 after acquiring an additional 36,451 shares in the last quarter. Institutional investors own 85.07% of the company's stock.

Insider Transactions at McKesson

In related news, EVP Michele Lau sold 2,725 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the transaction, the executive vice president directly owned 3,247 shares in the company, valued at approximately $3,214,530. The trade was a 45.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business's stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,868 shares of company stock worth $3,743,820. 0.08% of the stock is owned by insiders.

Analysts Set New Price Targets

MCK has been the subject of a number of research reports. Leerink Partners reissued an "outperform" rating and issued a $1,085.00 price objective on shares of McKesson in a research note on Thursday, March 5th. Mizuho increased their target price on McKesson from $880.00 to $885.00 and gave the stock a "neutral" rating in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of McKesson in a research report on Wednesday, December 10th. Evercore restated an "outperform" rating on shares of McKesson in a report on Thursday, March 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, McKesson presently has an average rating of "Moderate Buy" and a consensus price target of $960.93.

McKesson Stock Up 0.3%

Shares of McKesson stock opened at $943.43 on Tuesday. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The business has a 50 day moving average price of $896.29 and a 200-day moving average price of $828.19. The company has a market cap of $115.56 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 1.51 and a beta of 0.38.

McKesson (NYSE:MCK - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to analysts' expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.McKesson's quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts anticipate that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson's payout ratio is currently 9.43%.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.